Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03277352 · ClinicalTrials.gov registry record · Phase 1
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
A Phase 1 study, sponsored by Incyte Biosciences International Sàrl.
- Terminated
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT03277352 is a Phase 1 study that was terminated before completion, run by Incyte Biosciences International Sàrl. The registered enrollment target is 10 participants.
The verdict
NCT03277352, a Phase 1 study, was terminated before completion, sponsored by Incyte Biosciences International Sàrl.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies.
Interventions
- DRUG Pembrolizumab
- DRUG Epacadostat
- DRUG INCAGN01876
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2017-11-21 |
| Est. Completion | 2020-07-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03277352
The ClinicalTrials.gov registry entry for NCT03277352 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Biosciences International Sàrl, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT03277352 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03277352 about?
NCT03277352 is a clinical study titled "INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies". The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies.
What is the current status of trial NCT03277352?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2017-11-21. Estimated completion is 2020-07-01.
What interventions are being tested in trial NCT03277352?
The interventions under investigation include: Pembrolizumab (DRUG), Epacadostat (DRUG), INCAGN01876 (DRUG).
Who is sponsoring clinical trial NCT03277352?
This trial is sponsored by Incyte Biosciences International Sàrl, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.